Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EVSV is preparing to bring its expertise in organic fertilizers and other potential critical necessities to the industrial hemp farming market. The company has already been in conversations with parties currently engaged in the U.S. hemp sector.
In particular the company anticipates a joint venture announcement with a cannabis cultivation operation working to develop a proprietary hemp cultivar to be coming soon.
EVSV's plans to expand into the hemp market are part of the company's overall recently announced plans to expand its current service offerings.
The company recently announced plans to diversify its current government focused service offerings enabling the company to win a larger share of the approximate $45 billion in contracts awarded annually under U.S. Government General Services Administration (GSA) contracts.
"Based on a few unannounced majority events regarding municipal contracts that will be announced in the short run, it will have a significant impact financially resulting in 30-40% increase. 2018 was a record year but 2019 will be enormous. We are very happy with our core business at this point"
Hemp Farming Board of Advisors in conjunction with the company's new Hemp Farming Services initiative. The first three board members will join the Enviro-Serv team at the previously announced roll out its 2019 Hemp Farming Services Plan at the Southern US Hemp Conference and Expo.
Board members include Dr. David Roth and his wife Isabel Roth. Both are large hemp farming investors with projects in the states of New York and Colorado and are both certified in hemp farming and processing. The Roth's are also investors in Enviro-Serv's Hemp Farming Services initiative.
Also joining the Board, is David Santana, owner of Santana Farms, a 31-year farming operation in Homestead, Florida. Homestead has been selected by State officials as one of three cities for growing hemp in the state of Florida. Mr. Santana will play a key roll going forward representing Enviro-Serv in its roll-out of Hemp Farming Services.
In conjunction with the company's new strategy comes an updated shareholder communication strategy.
https://www.otcmarkets.com/stock/EVSV/news/Enviro-Serv-Inc-CEO-Talks-New-Opportunities-in-10-Billion-Hemp-Sector-in-Interview?id=208925
https://www.otcmarkets.com/stock/EVSV/news/Enviro-Serv-Targets-10-Billion-Hemp-Industry-in-Light-of-2018-Farm-Bill-Possibilities?id=207893
https://www.otcmarkets.com/stock/EVSV/news/Enviro-Serv-Announces-Hemp-Farming-Board-of-Advisors-to-Be-Introduced-at-Southern-US-Hemp-Conference-and-Expo?id=211038
KALY, NOUV and PURA are partners in a joint venture named US Cannabis Health for the purpose of together developing partnerships with pharmaceutical companies to develop cannabis pharmaceuticals. US Cannabis Health recently announced its first agreement with Generex Biotechnology, Corp. (OTCQB: GNBT).
http://ih.advfn.com/stock-market/USOTC/nouveau-life-pharmaceuticals-inc-pn-NOUV/stock-news/78968074/kali-extracts-and-nouveau-anticipate-5-million-in
"spinoff transaction is ultimately structured as a reverse merger involving comprehensive terms that include a change of control...The target public company, Nouveau Life Pharmaceuticals, Inc., (NOUV) ("NOUV") will be renamed after the execution of the prospective spinoff transaction...Once all terms of the comprehensive transaction have been completed, the current majority shareholder of PURA, is slated to also become the majority shareholder of target public company which will then be an independently traded cannabis cultivation company."
https://finance.yahoo.com/news/puration-announces-loi-spinoff-cannabis-131500268.html
IMHO, PURA's management is trying to put all the ducks in a row before releasing PR/News.
ACI Comglomerated - (Family of Businesses)
NOUV, USMJ, PURA, PJET
website is up:
https://shopusmj.cowts.studio/
"revenue tie-ins between KALY, PURA, NOUV, and GNBT...the business development potential outlined above may be contingent upon all parties succeeding and helping their partners as well as themselves."
http://www.goldmanresearch.com/201901081229/Opportunity-Research/kaly-multiple-shots-in-cbd-industry.html
yes sir, I agree. L2 is absolutely amazing. Extremely thin!!!
Multiple Shots on Goal in Multi-Billion Dollar Markets
January 08, 2019 - "Separately, management believes that based on feedback from those that were involved in the aforementioned study that the Kali-Extracts extracts may be superior to those of GW Pharmaceuticals (NASDAQ - GWPH - NR), the maker of Epidiolex. Plus, management proffered that as part of the development of its COPD therapies through its US Cannabis Health Partnership with Puration and Nouveau Pharma (OTC – NOUV – NR) the potential for Kali-Extracts to harness the patented RapidMist buccal cavity drug administration technology of Generex Biotechnology (OTC – GNBT – NR) would be a boon to all involved. Kali-Extracts’s joint venture agreement named US Cannabis Health with Puration and Nouveau was formed to combine their respective resources for the specific purpose of developing partnerships with major pharmaceutical companies to produce medical cannabis therapies.
Wellness
In the wellness arena, the early affirmation of its extract’s efficacy has occurred via sales of Puration Inc.’s CBD-infused beverage product which is based on Kali-Extracts’s IP. In fact, Puration could reach $1M in sales this year and $3M-$5M next year. Still, that is just the beginning. Various joint ventures and new product introductions in which Kali-Extracts has engaged are likely sources of near-term revenue for Kali-Extracts in the CBD-infused product market.
For example, as noted above, Puration and Kali-Extracts are part of a joint venture company called US Cannabis Health which was formed for the purpose of developing and marketing pharmaceutical applications and non-pharmaceutical wellness concentrates derived from Kali-Extracts’s patented extraction process. Puration, currently the sole licensee of the process will be producing the NuGenerex CBD HydroHealth High Alkaline Water. As part of this arrangement, Kali-Extracts will be developing custom CBD extracts for Puration to infuse into the NuGenerex CBD HydroHealth High Alkaline Water.
The Company is also producing its own products. Last month, Kali-Extracts announced it was launching its own line of hemp-derived CBD infused candies and vapes under the brand name HEMP4MULA. With an initial wholesale order pending Kali-Extracts’s completion of its first production run, the company expects to see HEMP4MULA CBD Gum on sale at retail later this month. Kali-Extracts’s Hemp4mula CBD Infused Chewing Gum will come in a blister back of 8 pieces with 10 mg each of hemp-derived CBD. Mints and gummies infused with CBD are expected to follow soon thereafter. HEMP4MULA vapes are also coming soon.
Kali-Extracts and Nouveau recently announced an agreement to expand NOUV’s current cultivation operations to include 100 adjacent acres dedicated to growing hemp under the new Farm Bill legalizing hemp farming just signed into law by President Trump. Kali-Extracts will construct a CBD extraction facility on site based on its proprietary and patented extraction process. In addition to the outdoor hemp cultivation, Nouveau will build a state-of-the-art greenhouse operation intended for the development of a proprietary hemp cultivar. Nouveau has a cannabis cultivation operation with facilities in the U.S. and Canada. The objective of the partnership is to develop a proprietary pharmaceutical grade hemp cultivar in addition to being a source of hemp supply for a myriad of industries in what both companies anticipate to be exploding demand in 2019.
KEY FIGURES
As noted above, the Company’s innovative extraction technology is already bearing fruit. It can be quantified in the success of the Puration beverages. Puration currently produces EVERx CBD Sports Water, the leading CBD infused water in the sports nutrition market. Puration has trailing twelve-month revenues of approximately $1 million. However, due to the aforementioned relationship with Generex, Puration received a $1M order at year-end related to the launch of NuGenerex CBD HydroHealth High Alkaline Water. It should be noted that $300,000 of the order is earmarked to Kali-Extracts as a CBD extraction contract. Clearly, the Puration relationship is a near term sales driver as its potential $3M - $5M in revenue for 2019 would certainly contribute to Kali-Extracts’ financials.
Separately, the Company was awarded a $100,000 wholesale order of its Hemp4mula CBD Infused Chewing Gum. The wholesale buyer plans to have Hemp4mula CBD Infused Chewing Gum available for sale at select retail drugstore locations and through the soon to be launched USMJ E-commerce Site from North American Cannabis Holdings, Inc. (OTC – USMJ – NR).
Finally, the Company and Nouveau anticipate up to $5 million in revenue from their hemp cultivation and extraction venture. On the heels of the hemp legalization, industry sources suggest that hemp farming could yield $50,000 per acre from the combination of CBD extraction and other uses of hemp. Thus, the 100-acre hemp cultivation operation could yield $5 million.
http://www.goldmanresearch.com/201901081229/Opportunity-Research/kaly-multiple-shots-in-cbd-industry.html
MIRAMAR, FL - January 7, 2019 - About Cannabis Therapies US Cannabis Health LOI
Generex Biotechnology has also stepped forward in the rapidly evolving and growing cannabis based therapies sector entering into an LOI with US Cannabis Health, a JV between Puration, inc. (PURA) Kali-Extracts, Inc. (KALY) and Nouveau Life Pharmaceuticals, Inc. (NOUV).The LOI includes an agreement for KALY to produce specialized CBD extracts for infusion into a bottled water to be produced by PURA under a private label for Generex.
https://ih.advfn.com/stock-market/USOTC/generex-biotechnology-corp-GNBT/stock-news/79003570/generex-biotechnology-introduces-treatment-alterna
Dallas, TX - January 7, 2019 - KALY is currently a partner in US Cannabis Health with Puration, Inc. (USOTC: PURA) and Nouveau (USOTC: NOUV) which has signed an LOI to explore the development of cannabis therapies in partnership with Generex Biotechnology (OTCQB: GNBT).
https://ih.advfn.com/stock-market/USOTC/nouveau-life-pharmaceuticals-inc-pn-NOUV/stock-news/79003841/kaly-kali-extracts-analyst-research-report-featu
NOUV mentioned again in today's PR from Generex
GNBT – Generex Biotechnology Plans Breast Cancer Vaccine Spinout and Dividend
https://www.gurufocus.com/news/794630/gnbt--generex-biotechnology-plans-breast-cancer-vaccine-spinout-and-dividend
Stock to Keep Your Eyes on: Nouveau Life Pharmaceuticals (OTC:NOUV)
https://stockdigest.info/2019/01/04/stock-to-keep-your-eyes-on-nouveau-life-pharmaceuticals-otcnouv/
Stock in the Wall Street Spotlight: Nouveau Life Pharmaceuticals (OTC:NOUV)
https://connectinginvestor.com/2019/01/04/stock-in-the-wall-street-spotlight-nouveau-life-pharmaceuticals-otcnouv/
yes, it was as if someone just flipped the switch and off it went
Agreed BottomTurn. IMHO, of all the companies within the ACI Comglomerated family...NOUV is the one and only one to have. The CEO believes that as well...
"hemp farming is much, much bigger than just CBD production. I am not understating anything when I tell you that hemp farming will have a massive economic impact worldwide, not just in the agriculture sector, but across the entire global economy. Legal hemp farming in the US will permeate through the pharmaceutical sector, the construction sector, the fashion sector and the energy sector to name just a few."
Shareholder Update - Dallas, Texas – January 4, 2019 – North American Cannabis Holdings, Inc. (USOTC: USMJ) (“USMJ”) today released a 2019 New Year message from the CEO and Chairman Steven Rash. Mr. Rash is also the President and Chairman of ACI Conglomerated, the majority shareholder of USMJ. His letter, included below in its entirety, provides an update on pending key events for USMJ and the USMJ family of companies to include, Puration, Inc. (USOTC: PURA) (“PURA”), Kali, Inc. (dba/Kali-Extracts) (USOTC: KALY), Nouveau Life Pharmaceuticals, Inc. (dba/Nouveau) (USOTC: NOUV) and Priority One Aviation (Pending Name Change)(USOTC: PJET)(“PJET”). ACI Conglomerated is the majority shareholder of all of the USMJ family of companies except for KALY. KALY is part of the family through contract. PURA has licensed KALY’s patented cannabis extraction process for the production of cannabis infused beverages and PURA and KALY are partners in a joint venture with NOUV called US Cannabis Health. Combined, with a specific by company breakout included in the letter below, the USMJ family of companies have an initial revenue goal totaling $20 million. As some of the companies in the family of companies have not yet set revenue goals, the total goal is expected to increase by the end of the first quarter. Read more below:
Dear Shareholders –
Let me start by wishing all a Happy New Year. I consider 2018 to have been a great year for the USMJ family of companies and I anticipate 2019 to be a pivotal year for the US cannabis industry at large and in turn, a tremendous year for USMJ, PURA, KALY, NOUV and PJET.
As I have noted in a previous communication, the legalization of hemp farming in the United States under the 2018 Farm Act is the biggest thing yet to happen to the cannabis sector world-wide and potentially the biggest event that will ever happen in the cannabis sector. On behalf of all our companies, I’m excited about the prospects of having US domestic hemp for the production of CBD. This will be a watershed event for KALY and PURA.
Even knowing the CBD aspect of legal hemp farming is a watershed event for KALY and PURA, I also know that legal hemp farming is much, much bigger than just CBD production. I am not understating anything when I tell you that hemp farming will have a massive economic impact worldwide, not just in the agriculture sector, but across the entire global economy. Legal hemp farming in the US will permeate through the pharmaceutical sector, the construction sector, the fashion sector and the energy sector to name just a few. Hemp farming is anticipated to generate $50,000 per acre and with NOUV launching its first 100 acres of hemp this year, you could see NOUV ringing $5 million in revenue in 2019.
While legal hemp farming, in my opinion, is the biggest event that will ever happen to the cannabis sector, I anticipate another cannabis sector event will get rolling this year that garners even more media attention than hemp farming. As 2019 winds down toward the 2020 Presidential Election, I anticipate we will see President Trump push for the legalization of recreational marijuana as part of his campaign. Between hemp farming and the likely advance toward the legalization of recreational marijuana, I expect 2019 to be a huge year for established entrepreneurial cannabis sector companies. I believe “USMJ” will become one of the most notable brand names in the cannabis sector.
So, with all the enthusiasm I can muster, Happy New Year to all. USMJ’s revenue goal for its soon to be launched ecommerce site is $10 million. PURA’s cannabis beverage sales goal is $5 million. KALY and NOUV anticipate $5 million in sales form their combined efforts with the 100-acre hemp farm. PJET has not yet set a revenue goal for its new AmeriCanna Cafe business and KALY and NOUV have not set individual revenue goals separate from their combined hemp farming initiative. In addition to the $20 million in combined sales goals for the USMJ family of companies, USMJ shareholders will soon be receiving a dividend of PJET stock, and PURA shareholders will soon be receiving a dividend of NOUV stock. The dividend issuance is taking a little longer than anticipated but is still on track. KALY has recently updated all its financial reports required by OTCMarkets and anticipates the OTCMarkets site to soon reflect KALY’s current filing status. KALY also anticipates publishing an analyst research report on Tuesday, January 8th, 2019 to provide shareholders with an extensive market analysis of the company’s business plan and progress toward its business plan objects.
Please keep a lookout on OTCMarkets and each of the companies’ websites for the latest updates in what we expect to be a very exciting 2019.
Sincerely,
Steven Rash
CEO and Chairman
USMJ and ACI Conglomerated
www.growusmj.com
www.purationinc.com
www.kali-extracts.com
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Steven Rash
CEO North American Cannabis Holdings, Inc.
info@aciconglomerated.com
+1-800-861-1350
01/03/2019 @ 11:33AM - US Cannabis Health LOI with Generex Biotechnology
"Generex Biotechnology has also stepped forward in the rapidly evolving and growing cannabis based therapies sector entering into an LOI with US Cannabis Health, a JV between Puration, inc. (PURA), Kali-Extracts, Inc. (KALY) and Nouveau Life Pharmaceuticals, Inc. (NOUV). The LOI includes an agreement for KALY to produce specialized CBD extracts for infusion into a bottled water to be produced by PURA under a private label for Generex."
Generex Biotechnology Makes Major Advance On $22 Billion Wound Care Market Announcing Milestone Agreement
https://ih.advfn.com/stock-market/USOTC/generex-biotechnology-corp-GNBT/stock-news/78984862/generex-biotechnology-makes-major-advance-on-22-b
NOUV is the backbone to ACI Comglomerate. Before the manufacturing of any products, it must be cultivated. NOUV has a cannabis cultivation operation with facilities in the U.S. and Canada. NOUV’s objective in the partnership is to develop a proprietary pharmaceutical grade hemp cultivar in addition to being a source of hemp supply for a myriad of industries in what management anticipates to be exploding demand in 2019.
"Go into distribution if you want to double revenue. In retail it's always distribution. And you're talking about making straight money, the best margins are in cultivation and manufacturing. Those are the highest margin businesses. Manufacturing is all about the creation of the oil. All your cogs go down with distribution, like any other retail business." - Steve Gormley is the chief executive of International Cannabrands
https://www.forbes.com/sites/lcarrel/2018/12/30/cannabis-companies-expect-big-growth-after-trump-legalizes-hemp/#43cc4579342c
Kali-Extracts and Nouveau Announce Cannabis Extraction Partnership For Canadian Recreational
DALLAS, TX - December 21, 2018 -- InvestorsHub NewsWire -- Kali, Inc. (dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced plans with Nouveau Life Pharmaceuticals (USOTC: NOUV) to use KALY’s patented cannabis extraction process in Canada. NOUV has a cannabis cultivation business with operations in the U.S. and Canada. The two companies will work together to produce cannabis extracts utilizing KALY’s patented cannabis extraction process for the recreational marijuana market.
KALY currently produces pharmaceutical grade cannabis extracts that have been involved in multiple clinical trials in addition to utilizing its patented cannabis extraction process in the production of CBD infused nutrition and wellness products to include its own Hemp4mula and CBD infused waters produced by Puration, Inc. (USOTC: PURA) (“PURA”).
KALY is partners with PURA and NOUV in a joint venture named US Cannabis Health for the purpose of together developing partnerships with pharmaceutical companies to develop cannabis pharmaceuticals. US Cannabis Health recently announced its first agreement with Generex Biotechnology, Corp. (OTCQB: GNBT).
To learn more about the KALY and NOUV project announced today, follow developments online at www.kali-extracts.com.
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Kali, Inc.
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Kali-Extracts Analyst Research Report From Goldman Small Cap Research Expected Next Week
DALLAS, TX -- December 28, 2018 -- InvestorsHub NewsWire -- Kali, Inc. (dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced an Analyst Research Report covering the company’s new business direction after acquiring a patented cannabis extraction operation is expected to be published next week. On November 15th, the company announced the acquisition of NCM Biotech in a transaction that changed the business direction of the company. After updating all required filings to bring the company into compliance with its required OTCMarkets reports, KALY management subsequently announced engaging Goldman Small Cap Research to initiative coverage of KALY’s new assets and business direction. The purpose of this report is to provide shareholders and interested investors more comprehensive information on the company’s current operations in a single document. The report will be filed on the OTCMarkets site. It will include detailed asset and business descriptions, operational financial analysis, comparisons to similar businesses, market forecasts and KALY specific forecasts. The purpose of the report is to enhance the OTCMarkets’ required disclosures by providing information on the current operations in addition to the OTCMarkets reports on historical operations.
Recent KALY milestones published by the company anticipated to be included in the analyst report include:
Kali-Extracts, Inc. Releases Preclinical Research Study Results on Therapy for Respiratory Disease Driving $11 Billion Treatment Market
Kali-Extracts Inc. Announces $300,000 Contract to Produce Hemp-Derived CBD Extract for Puration Inc.
KALY - Kali-Extracts Announces $100,000 Order of its Hemp4mula CBD Infused Chewing Gum Available Soon on USMJ E-commerce Site
Kali-Extracts and Nouveau Announce 100 Acer Hemp Farm and CBD Extraction Facility Made Possible By New Farm Bill
KALY produces pharmaceutical grade cannabis extracts that have been involved in multiple clinical trials in addition to utilizing its patented cannabis extraction process in the production of CBD infused nutrition and wellness products to include its own Hemp4mula and CBD infused waters produced by Puration, Inc. (USOTC: PURA) (“PURA”).
KALY is partners with PURA and Nouveau Life Pharmaceuticals (dba Nouveau) (USOTC: NOUV) (“NOUV”) in a joint venture named US Cannabis Health for the purpose of together developing partnerships with pharmaceutical companies to develop cannabis pharmaceuticals. US Cannabis Health recently announced its first agreement with Generex Biotechnology, Corp. (OTCQB: GNBT).
Learn more about the KALY at www.kali-extracts.com.
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Kali, Inc.
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
NEWS! Kali-Extracts Announces Strong Response To Patented Cannabis Extraction Franchise
DALLAS, TX -- December 27, 2018 -- InvestorsHub NewsWire -- Kali, Inc. (dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced receiving a high volume of inquiries in response to recently making public its plans to launch a hemp-derived CBD extraction franchise business. KALY disclosed the plans following President Trump signing the Farm Bill legalizing hemp farming into law. KALY owns and operates a patented cannabis extraction process - U.S. Patent No. 9,199,960 entitled 'METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT'. The company has conducted numerous preclinical trials for a variety of disease therapies based on cannabis extracts derived from its cannabis process. The company also has experience producing commercial extractions for infusion into nutrition and wellness products. Hemp farming in the US is anticipated to explode in 2019 now that US Federal Government has legalized it. KALY’s franchise process will deploy trained extractors with a patented and proven process nationwide. The response rate from KALY’s initial announcement is an early indication of substantial revenue growth potential in 2019. Look for an upcoming analyst research report on KALY coming soon.
KALY produces pharmaceutical grade cannabis extracts that have been involved in multiple clinical trials in addition to utilizing its patented cannabis extraction process in the production of CBD infused nutrition and wellness products to include its own Hemp4mula and CBD infused waters produced by Puration, Inc. (“PURA”).
KALY is partners with PURA and Nouveau Life Pharmaceuticals in a joint venture named US Cannabis Health for the purpose of together developing partnerships with pharmaceutical companies to develop cannabis pharmaceuticals. US Cannabis Health recently announced its first agreement with Generex Biotechnology, Corp.
To learn more about the KALY and NOUV project announced today, follow developments online at www.kali-extracts.com.
Happy Holidays to you and yours.
NOUV – Cannabis Cultivation Business & Joint Venture
US Cannabis Health is a joint venture involving Puration, Inc., Kali, Inc., and Nouveau Life Pharmaceuticals, Inc. US Cannabis Health was formed for the development of cannabis pharmaceutical and wellness products. The cannabis pharmaceuticals market is forecasted to reach a $50 billion sales by 2029.
December 21, 2018
Kali-Extracts and Nouveau Announce Cannabis Extraction Partnership For Canadian Recreational Marijuana Market
DALLAS, TX - December 21, 2018 -- InvestorsHub NewsWire -- Kali, Inc. (dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced plans with Nouveau Life Pharmaceuticals (USOTC: NOUV) to use KALY’s patented cannabis extraction process in Canada. NOUV has a cannabis cultivation business with operations in the U.S. and Canada. The two companies will work together to produce cannabis extracts utilizing KALY’s patented cannabis extraction process for the recreational marijuana market.
KALY currently produces pharmaceutical grade cannabis extracts that have been involved in multiple clinical trials in addition to utilizing its patented cannabis extraction process in the production of CBD infused nutrition and wellness products to include its own Hemp4mula and CBD infused waters produced by Puration, Inc. (USOTC: PURA) (“PURA”).
KALY is partners with PURA and NOUV in a joint venture named US Cannabis Health for the purpose of together developing partnerships with pharmaceutical companies to develop cannabis pharmaceuticals. US Cannabis Health recently announced its first agreement with Generex Biotechnology, Corp. (OTCQB: GNBT).
December 20, 2018
The Joint Venture (JV) partnership with KALY and NOUV is proceeding even better than anticipated.
PURA recently spun-off its cannabis cultivation operation with facilities in the U.S. and Canada to NOUV. In conjunction with the spin-off, a portion of the consideration that PURA received from NOUV was slated to be converted into common stock and that NOUV common stock was to be issued to shareholders of PURA. Specifically, PURA sold its cannabis cultivation business to NOUV in exchange for a $1.2 million convertible note with a commitment that the note would promptly be converted to common shares of NOUV and that those converted shares would be distributed in a stock dividend to the shareholders of PURA. PURA and NOUV originally planned to wait for NOUV to execute a reverse spilt before executing the dividend distribution. While pursuing that objective, it became clear the execution of the reverse split would take some time. As NOUV updates its filings and executes on its business plan with the new cannabis cultivation operation, optimistically, a reverse split of NOUV might not be necessary. So, PURA and NOUV management have explored alternative options. In light of the fact that the common shares of NOUV issued to PURA shareholders will not be immediately free trading and will have to season to be free trading under an exemption from registration, PURA and NOUV have resolved to issue a dividend of preferred shares convertible into common shares. In this way, a dividend of equity can be rapidly issued and the seasoning of shares for exemption can begin. If a NOUV reverse proceeds as originally planned, then shareholders will receive the original allocation of 1 common share for every 5 shares of PURA. If a reverse proves unnecessary, then the conversion of preferred shares into common shares will be adjusted accordingly to affect an equal dividend allocation.
Kali, Inc. (dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) and Nouveau Life Pharmaceuticals, Inc. (dba/Nouveau, Inc) (USOTC: NOUV) (“NOUV”) today announced an agreement to expand NOUV’s current cultivation operations to include 100 adjacent acres dedicated to growing hemp under the new Farm Bill legalizing hemp farming and anticipated to be signed into law later today by President Trump. KALY will construct a CBD extraction facility on site based on KALY’s patented extraction process. In addition to the outdoor hemp cultivation, NOUV will build a state-of-the-art greenhouse operation intended for the development of a proprietary hemp cultivar.
NOUV has a cannabis cultivation operation with facilities in the U.S. and Canada. NOUV’s objective in the partnership announced today with KALY is to develop a proprietary pharmaceutical grade hemp cultivar in addition to being a source of hemp supply for a myriad of industries in what management anticipates to be exploding demand in 2019.
KALY, NOUV and PURA are partners in a joint venture named US Cannabis Health for the purpose of together developing partnerships with pharmaceutical companies to develop cannabis pharmaceuticals. US Cannabis Health recently announced its first agreement with Generex Biotechnology, Corp. (OTCQB: GNBT).
Week of November 5th, 2018
NOUV, PURA, KALY, NCM meeting in Dallas.
Kali and NCM are meeting this week in Dallas to both consummate the acquisition and strategize with Puration, Inc. (PURA) and Nouveau Life Pharmaceuticals, Inc. on the recent formation of a joint venture (JV) company to develop cannabis pharmaceutical products. Kali has partnered with PURA and NOUV to form US Cannabis Health, a JV company formed for the development of cannabis pharmaceutical and wellness products. The cannabis pharmaceuticals market is forecasted to reach a $50 billion sales by 2029.
"Representatives of the three companies plan to meet next week in Dallas, Texas at Puration’s headquarters. Look for more news on the JV following next week’s meetings."
https://finance.yahoo.com/news/kali-inc-announces-us-cannabis-155428738.html
November 02, 2018
SARASOTA, Fla., Nov. 02, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali, Inc. (USOTC: KALY) today published the online presentation included here below to detail the strategy behind the recently announced plans with Puration, Inc. (USOTC: PURA) and Nouveau Life Pharmaceuticals, Inc. (USOTC: NOUV) to form a joint venture (JV) company to develop cannabis pharmaceutical products. The cannabis pharmaceutical market is anticipated to reach a value of $50 billion by 2029. Nouveau has recently acquired a cannabis cultivation operation from Puration. In the JV, Nouveau would be tasked with developing a proprietary pharmaceutical grade hemp cultivar. The acquired cannabis cultivation has already initiated efforts toward developing a proprietary, pharmaceutical grade hemp cultivar.
https://finance.yahoo.com/news/kali-inc-announces-us-cannabis-155428738.html
October 29, 2018
"Kali, Inc. (USOTC: KALY) today announced entering into discussions with Puration, Inc. (USOTC: PURA) and Nouveau Life Pharmaceuticals, Inc. (USOTC: NOUV) to explore forming a joint venture company between the three to develop cannabis pharmaceutical products...Look for more info on Kali’s plans with NCM Biotech and Puration and Nouveau later this week in a management presentation on the company’s comprehensive post acquisition business plan."
https://finance.yahoo.com/news/kali-inc-enters-discussions-puration-150149527.html
October 4, 2018
"In addition to PURA's plan to file its 2018 Q3 report on or before November 12th, NOUV management plans to bring NOUV current with its reporting requirements in the same time frame."
https://finance.yahoo.com/news/puration-inc-targets-november-15th-125000284.html
NOUV remains to be the backbone to this joint venture. Before any products can be extracted or made, the cannabis must be cultivated. NOUV is in a very, very good position.
“Some feedback has specifically indicated that a number of our candidate pharmaceutical products under development have a greater efficacy potential than GW Pharmaceutical products and candidate products.”
https://finance.yahoo.com/news/kali-inc-present-strategy-entering-133802344.html
If this Joint Venture can produce products with greater efficacy than GW Pharmaceutical, the future is very promising for the three companies involved. GW Pharmaceutical is trading on the NASDAQ (NASDAQ:GWPH). Currently it has attracted attention from big companies such as Constellation Brands, Coca-Cola, Heineken, and others. These are only beverage brands, soon it will attract major top tier pharmaceutical companies as well.
"To streamline and concentrate all its resources on the production of cannabis infused beverages, Puration has recently spun-off its cannabis cultivation operation. The spinoff was affected through the execution of a securities exchange agreement with Nouveau Life Pharmaceuticals, Inc., (NOUV) (“NOUV”). Now that the securities exchange agreement between NOUV and Puration is finalized, NOUV is working to rapidly come current with its financial reports. The first steps leading to the stock dividend distribution are underway, and the combined management teams are committed."
https://www.purationinc.com/cannabisbeveragebusinessplan/
"The company acquired First Choice Nursery last year to establish a 25-greenhouse operation in the first step of a plan to grow the operation to 400 greenhouses. First Choice Nursery began booking its first sales in the first quarter of this year.
First Choice Nursery which has an existing twenty-five greenhouse facility in Texas. The company has the opportunity to expand to an additional 400 irrigated greenhouse pads ready for buildout. Renovations have already begun. Puration has a U.S. Patented Cannabis Extraction process licensed from NCM Biotech. The license of the process to Puration is the first and only license NCM Biotech has executed. R&D with NCM Biotech's patented process has demonstrated a high potential for bringing FDA approved pharmaceutical products to market for the treatment of multiple neurological disorders and cancer.
"I have received doctor feedback from more than one of our research initiatives that extracts coming from NCM Biotech's patented process are superior in purity and quality to any other available cannabis extracts," said Frederick Ferri, CEO and Founder of NCM Biotech. "Some feedback has specifically indicated that a number of our candidate pharmaceutical products under development have a greater efficacy potential than GW Pharmaceutical products and candidate products."
Puration and NCM Biotech plan to expand existing University Research relationships to include a portion of the greenhouse facility being utilized to develop a proprietary strain of CBD. Puration will use proceeds from the balance of the traditional nursery operation to expand the operation into its full 400 greenhouse potential. The operation is located in a region of East Texas well known for nursery operations. Texas has recently legalized medical marijuana and is pending the issuance of its first licenses. Puration intends to transition to marijuana growing overtime in conjunction with the legalization process. In the meantime, Puration anticipates the traditional nursery operations have the potential to expand to as high as $16 million in annual sales. Medical Marijuana sales can be substantially higher."
A major component of having the best cannabis extract is having the best cannabis plants from which to extract cannabinoids. Cannabis cultivation is a natural extension of Puration's long-term development. Being headquartered in Texas, it made sense to take advantage of new medical marijuana laws in Texas. Accordingly, Puration acquired an older conventional nursery operation, First Choice Nursery, and immediately began renovations. Puration is now utilizing the 25-greenhouse facility conventionally and anticipates growing to $1 million in annual sales from conventional nursery operations. First Choice Nursery started booking its first sales since the Puration acquisition in the first quarter of this year. Puration has an option on acquiring another 400 greenhouse pads. Puration is working to secure a medical marijuana cultivation license in Texas with future plans to migrate the conventional nursery operation into a cannabis cultivation operation.
https://finance.yahoo.com/news/puration-cannabis-cultivation-business-takes-131300744.html
Puration's Cannabis Cultivation Foundation
Puration has implemented a long-term cannabis cultivation strategy to navigate the evolving legal environment and ultimately establish a recognized brand name in the cannabis marketplace. Through last year's acquisition of First Choice Nursery, Puration has already set up a 25-greenhouse operation in its home state of Texas where limited medical marijuana legalization has passed. The company is working to establish a university-backed cannabis cultivation research facility within the 25-greenhouse operation. In the meantime, the facility is financed by growing conventional household and landscape plants. It is expected to generate $1 million in revenue this year and self-finance the expansion of the 25-greenhouse operation into as many as 400-greenhouses. Once recreational marijuana is legal either through state or federal law, the Texas facility will be in a leadership position with a robust production facility ready-to-go and a university research backed cultivation process in place.
Canadian Cannabis Farmers Co-Op Business Plan
The acquisition of Canadian Cannabis Farmers Co-Op positions Puration for the estimated $5 billion recreational marijuana market expected to be legalized nationwide in Canada this summer. With the acquisition, Puration now has in-house cultivation experience garnered from the operation of a licensed medical marijuana facility of substantial size. The company plans to apply for a recreational license and anticipates its medical marijuana experience to be of benefit in the recreational license application process. Similar to other Canadian marijuana sector companies such as Canopy Growth Corp. (TWMJF), Aurora Cannabis (ACBFF), Aphria (APHQF), MedReleaf (MEDFF), and OrganiGram Holdings (ORGMF). Puration has plans to build substantial in-house operations. The company has already received interest from investors in backing the construction of facilities for pursuing the Canadian legal marijuana market. However, in addition to building out in-house operations, Puration plans to take its acquired expertise to what it expects to be a robust micro-cultivation and micro-processing market. Health Canada recently announced plans to introduce new micro-cultivation and micro-processing licenses. A micro-cultivation license would be issued to an authorized plant canopy area of less than 200 square meters (2,153 square feet), and a micro-processing license allowed for those processing less than 600 kilograms, or 1,323 pounds, of dried cannabis a year. The legalization of recreational marijuana in Canada also includes individual cultivation for up to four plants. Puration plans to serve the micro-cultivation, micro-processing and home-growers marketplace with products and services necessary for production. By establishing a recognized brand name in cannabis cultivation from its in-house production, Puration expects to leverage its brand name to tap into the more profitable micro-cultivation, micro-processing and home-growers marketplace. To help illustrate the opportunity, consider the micro-brewery and home brewing marketplace in the United States alone. Retail dollar sales for craft micro-brewed beer in the U.S. is approximately $26.0 billion, accounting for more than 23% of the overall $111.4 billion U.S. beer market.
https://finance.yahoo.com/news/puration-presents-cannabis-cultivation-strategy-150000832.html
“Puration had initiated a project to expand its extraction process upstream into cannabis cultivation. Having the best extracts depends not only on the extraction process itself, but also on the quality of the cannabis being extracted. Puration has cultivation operations in the United States and Canada.”
https://www.purationinc.com/extraction
Puration Inc Targets November 15th to Declare 1:5 Cannabis Cultivation Stock Dividend
Kali Inc. Enters Discussions with Puration and Nouveau Life Pharmaceuticals to Enter $50 Billion Cannabis Pharmaceuticals Market
NOUV - Important Notes
"Now that the securities exchange agreement between NOUV and Puration is finalized, NOUV is working to rapidly come current with its financial reports." - https://www.purationinc.com/cannabisbeveragebusinessplan/
"NOUV management plans to bring NOUV current with its reporting requirements in the same time frame...on or before November 12th"
https://finance.yahoo.com/news/puration-inc-targets-november-15th-125000284.html
"Management has shown no interest in reverse splits"
Nouveau Life Pharmaceuticals (USOTC: NOUV) ($0.0003) - NOUV has recently acquired a cannabis cultivation operation from cannabis industry juggernaut Puration, Inc. (USOTC: PURA). The company is issuing a stock dividend to the shareholders of PURA. The dividend, set to be declared on the 15th of November, and the overall business relationship with PURA stands to potentially drive NOUV into the double digits between now and the 15th of November...Management has shown no interest in reverse splits and seems content with working in the sub penny range continuing to incubate new cannabis sector enterprises and giving shareholders the opportunity to enjoy one triple zero to double zero run after another.
https://ih.advfn.com/p.php?pid=nmona&article=78569240
New 52Wk high coming today!
Your analysis is spot on MoneyMaker. great read. thanks
"livestream starting soon"
"reverse split of NOUV might not be necessary"
https://ih.advfn.com/stock-market/USOTC/puration-inc-pc-PURA/stock-news/78931172/pura-puration-2018-sales-exceed-1-million-goal
Thinner as it moves up
Agreed! Management has no issues with releasing PR's as evidenced by the other partners, it should easily carry it to multiple pennies.
Trump is supposedly going to sign the Farm Bill at 11:30 today
"NOUV has a cannabis cultivation operation with facilities in the U.S. and Canada!!!"
Supply vs. Demand..."source of hemp supply for a myriad of industries" but the demand for the proprietary hemp cultivar is the "golden ticket".
Dallas, TX -- December 20, 2018 -- InvestorsHub NewsWire -- Kali, Inc. (dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) and Nouveau Life Pharmaceuticals, Inc. (dba/Nouveau, Inc) (USOTC: NOUV) (“NOUV”) today announced an agreement to expand NOUV’s current cultivation operations to include 100 adjacent acers dedicated to growing hemp under the new Farm Bill legalizing hemp farming and anticipated to be signed into law later today by President Trump. KALY will construct a CBD extraction facility on site based on KALY’s patented extraction process. In addition to the outdoor hemp cultivation, NOUV will build a state-of-the-art greenhouse operation intended for the development of a proprietary hemp cultivar.
KALY produces pharmaceutical grade cannabis extracts that have been involved in multiple clinical trials in addition to utilizing its patented cannabis extraction process in the production of CBD infused nutrition and wellness products to include its own Hemp4mula and CBD infused waters produced by Puration, Inc. (USOTC: PURA) (“PURA”).
NOUV has a cannabis cultivation operation with facilities in the U.S. and Canada. NOUV’s objective in the partnership announced today with KALY is to develop a proprietary pharmaceutical grade hemp cultivar in addition to being a source of hemp supply for a myriad of industries in what management anticipates to be exploding demand in 2019.
KALY, NOUV and PURA are partners in a joint venture named US Cannabis Health for the purpose of together developing partnerships with pharmaceutical companies to develop cannabis pharmaceuticals. US Cannabis Health recently announced its first agreement with Generex Biotechnology, Corp. (OTCQB: GNBT).
To learn more about the KALY and NOUV project announced today, follow developments online at www.kali-extracts.com.
https://ih.advfn.com/stock-market/USOTC/kali-inc-KALY/stock-news/78930058/kali-extracts-and-nouveau-announce-100-acer-hemp-f
President Trump has indicated his intention to sign the Farm Bill legalizing hemp farming into law tomorrow, Thursday, December 20th, 2018.
https://ih.advfn.com/stock-market/USOTC/kali-inc-KALY/stock-news/78922743/kaly-kali-extracts-anticipates-president-trump-s
43.2M in volume thus far. NOUV is the backbone to this whole conglomeration.
that would be the best Christmas gift ever! i agree...something special is brewing here.